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Abstract 
IgG antibodies cause inflammation and organ damage in autoimmune diseases such 
as systemic lupus erythematosus (SLE). We investigated the metabolic profile of 
macrophages isolated from inflamed tissues in immune complex (IC)-associated 
diseases, including SLE and rheumatoid arthritis, and following IgG Fcγ receptor 
cross-linking. We found that human and mouse macrophages undergo a switch to 
glycolysis in response to IgG IC stimulation, mirroring macrophage metabolic 
changes in inflamed tissue in vivo. This metabolic reprogramming was required to 
generate a number of pro-inflammatory mediators, including IL-1β, and was 
dependent on mTOR and hypoxia-inducible factor (HIF)1α. Inhibition of glycolysis, or 
genetic depletion of HIF1α, attenuated IgG IC-induced activation of macrophages in 
vitro, including primary human kidney macrophages. In vivo, glycolysis inhibition led 
to a reduction in kidney macrophage IL-1β and reduced neutrophil recruitment in a 
murine model of antibody-mediated nephritis. Together, our data reveal the 
molecular mechanisms underpinning FcγR-mediated metabolic reprogramming in 
macrophages and suggest a novel therapeutic strategy for autoantibody-induced 
inflammation, including lupus nephritis.  
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Significance statement 
IgG antibodies are a key component of adaptive humoral immunity but can cause 
organ damage if they bind self-antigen, as occurs in the autoimmune disease 
systemic lupus erythematosus (SLE).  Many of the pro-inflammatory effects of IgG 
are mediated by ligating Fc gamma receptors (FcγRs) expressed by tissue-resident 
leukocytes such as macrophages. One of the most serious complications of SLE is 
kidney inflammation – lupus nephritis. Here we show that IgG ligation of FcγRs on 
macrophages in the kidney leads to a change in their metabolism, resulting in a 
switch towards glycolysis. Administration of a glycolysis inhibitor attenuated IgG-
associated kidney macrophage activation, pro-inflammatory cytokine secretion and 
kidney inflammation. Therefore, manipulating macrophage metabolism may be a 
















IgG antibodies play an important role in defence against infection, but can cause 
inflammation and organ damage in autoimmune diseases such as systemic lupus 
erythematosus (SLE) (1). Patients with SLE have circulating antibodies that bind to a 
variety of self-antigens, resulting in IgG immune complex (IC) deposition in skin, 
joints and kidneys causing organ damage by activating complement and local 
immune cells (2, 3). Current treatments for lupus and other autoantibody-mediated 
diseases do not adequately control disease activity and tissue damage, and are 
associated with significant side-effects (4), therefore the identification of new 
therapeutic targets is a major unmet clinical need. Fcγ receptors (FcγRs) bind IgG IC 
and are expressed by many immune cells, including tissue-resident macrophages (5, 
6). Polymorphisms in FCGR genes are associated with increased susceptibility to 
SLE and other autoimmune diseases (7-9), confirming their importance in disease 
pathogenesis. FcγRs may be activating (in humans FcγRIIA, IIIA, IIIB) or inhibitory 
(FcγRIIB), and the balance of these two inputs determines the activation threshold 
and the magnitude of the inflammatory response to IgG IC (1, 10). Macrophages are 
tissue-resident immune cells that can respond to local immune challenges and when 
stimulated by IgG IC, produce cytokines such as IL-6, TNFα and IL-1β, as well as 
inflammatory mediators including prostaglandins and reactive oxygen species (ROS) 
(6, 7, 10-12). Given their potent pro-inflammatory effects in tissues, macrophages 
are an obvious therapeutic target in antibody-mediated autoimmunity. Indeed, mice 
deficient in activating FcγRs (13) or with macrophage-specific over-expression of the 
inhibitory FcγRIIB show less severe autoantibody-induced nephritis (14). These data 
suggest that inhibition of FcγR-dependent macrophage activation may be a useful 
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treatment strategy in lupus and in other autoimmune diseases where antibodies play 
a pathogenic role. 
 
There has been a recent appreciation that immune cells undergo metabolic 
reprogramming in response to local pathogen-derived signals and cytokines.  
Indeed, these changes in cellular metabolism can profoundly influence the nature of 
the immune response produced (15, 16). For example, macrophages activated by 
the toll-like receptor (TLR)-4 ligand lipopolysaccharide (LPS), known as M(LPS) or 
M1 macrophages (17), undergo an increase in glycolysis but a reduction in Krebs 
cycle associated oxidative phosphorylation (OXPHOS) and have a pro-inflammatory 
phenotype (18, 19), whereas macrophages generated by IL-4 stimulation (M(IL-4) or 
M2 macrophages (17)) retain high OXPHOS and have anti-inflammatory properties 
(18, 19).  To date, there has been little consideration of how FcγR cross-linking by 
IgG IC affects metabolic processes in macrophages, and this information is 
important for our understanding of the pathogenesis of diseases characterised by 
antibody-mediated inflammation. Of note, although immune complex stimulation 
results in the production of pro-inflammatory cytokines by macrophages (11, 12), the 
signalling cascade downstream of FcγR is distinct from TLR signalling, involving 
SYK, PI3K and MAPK (1, 5). Indeed, the addition of IgG IC to LPS-stimulated 
macrophages can even attenuate inflammation (20). This raises the question of 
whether FcγR cross-linking on macrophages may have distinct and specific effects 
on macrophage metabolism.  
 
Here we show that tissue macrophages in IC-associated disease exhibit a glycolytic 
transcriptional signature, which is shared with macrophages following IgG IC 
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stimulation in vitro. In response to IgG IC stimulation macrophages upregulate 
glycolytic genes and undergo a switch to aerobic glycolysis. This metabolic 
reprogramming was required to generate a number of pro-inflammatory mediators 
and cytokines, suggesting that this pathway could be activated in antibody-mediated 
tissue inflammation in vivo, and potentially represents a useful therapeutic target. In 
keeping with this, inhibition of glycolysis attenuated IgG IC-induced IL-1β production 
by kidney macrophages in mice and humans, and reduced neutrophil recruitment 
and inflammation in nephrotoxic nephritis.  Together, our data reveal the cellular 
molecular mechanisms underpinning FcγR-mediated metabolic reprogramming in 
macrophages and that this switch occurs in kidney macrophages in vivo following 
IgG IC challenge. Inhibition of macrophage glycolysis ameliorated autoantibody-




FcγR cross-linking induces a transcriptional glycolytic switch in macrophages 
To address the question of whether inflammation associated with autoantibody IC 
deposition in tissues results in changes in macrophage metabolism, we assessed 
the transcriptional profiles of macrophages obtained from inflamed tissues. In human 
synovial macrophages isolated from patients with RA (Fig. 1A), and in kidney F4/80+ 
macrophages from mice with NZB/W lupus nephritis (Fig. 1B, SI Appendix, Fig. 
S1A), we observed an enrichment of glycolysis pathway genes compared to control 
macrophages. Kidney macrophages may arise from yolk-sac precursors or may be 
monocyte-derived that are F4/80hiCD11bint and F4/80intCD11bhi respectively (21), 
and may differ in their functional characteristics (22). To determine if the metabolic 
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profile of both macrophage subsets was altered in IC-mediated inflammation, we 
performed single cell RNA sequencing (scRNAseq) on renal myeloid cells sorted 
from a second model of murine nephritis, MRL-lpr mice and from control MRL/MpJ 
mice. Several clusters of cells could be distinguished with two major groups evident, 
mononuclear phagocyte (MNP)1, with transcriptional similarity to yolk-sac derived 
F4/80hi macrophages and MNP2 that were transcriptionally similar to monocyte-
derived macrophages and included a monocyte cluster (Fig. 1C, D).  In non-
diseased MRL/MpJ kidney monocytes and macrophages, fatty acid metabolism 
genes were enriched (Fig. 1E). In contrast, in MRL-lpr mice, glycolysis and 
OXPHOS genes were increased in kidney MNPs, with glycolysis genes particularly 
enriched in monocyte-derived macrophages (Fig. 1E). Although informative of 
potential metabolic changes induced by IgG, macrophages isolated from inflamed 
tissues may be influenced by a variety of tissue- and disease-specific factors, 
including local cytokines and danger-associated molecular patterns, as well as the 
exact nature of the IgG immune complexes. Furthermore, transcriptional changes in 
metabolic pathway genes require validation to definitively confirm cellular metabolic 
adaptations. To better characterise the specific effect of isolated FcγR cross-linking 
by IgG IC on macrophage metabolism, we stimulated murine bone-marrow-derived 
macrophages (BMDM) with a model IgG IC (ovalbumin opsonised with IgG (Ova-IC)) 
(23, 24) and assessed gene expression (SI Appendix, Fig. S1B).  We observed a 
significant enrichment of glycolysis-associated genes following FcγR crosslinking 
(Fig. 1F, SI Appendix, Fig. S1B), including increased transcripts of key enzymes 
and transporters required for glycolysis, such as Hk2, Ldha, and Slc2a1 (Fig. 1G), 
which we confirmed using real time quantitative (q) PCR (Fig. 1H).  Similarly, in 
human monocytes stimulated with plate-coated IgG (c-IgG), we also observed an 
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enrichment of glycolysis-associated genes (SI Appendix, Fig. S1C).  In addition to 
an increase in glycolysis genes, we also observed reduced expression of genes 
associated with fatty acid metabolism in IgG IC disease-associated macrophages 
and in murine macrophages following FcγR crosslinking (Fig. 1A, B, E), specifically, 
fatty acid catabolism pathway genes (Fig. 1I). In vivo, inflamed NZB/W renal and RA 
synovial macrophages showed globally similar transcriptional changes to BMDM 
stimulated with IgG IC, with an increase in FcγR-inducible genes and a reduction in 
FcγR-suppressed genes in BMDMs, suggesting that FcγR signalling may underpin 
the macrophage metabolic phenotype in vivo (SI Appendix, Fig. S1D). Furthermore, 
we observed a positive correlation between the induction of glycolysis pathway 
genes and the expression of the in vitro BMDM-derived FcγR-associated gene 
signature in NZB/W renal macrophages (Fig. 1J), supporting the conclusion that 
these pathways are causally linked. Analysis of FcγR expression in renal 
macrophages from nephritic NZB/W mice demonstrated an increase in activating 
FcγR expression and reduction in FcγRIIB (SI Appendix, Fig. S1E), resulting in an 
increase in FcγR A:I ratio compared to pre-nephritic mice or mice in remission (SI 
Appendix, Fig. S1F). Therefore, inflamed tissue macrophages are primed for IgG 
ligation and exhibit an activated FcγR-associated transcriptional signature, including 
a switch to glycolysis. To ensure that this was not due to contamination of IgG IC 
with a toll-like receptor (TLR) ligand such as lipopolysaccharide (LPS), we assessed 
glycolysis-associated genes in TLR2/4-deficient BMDMs and observed a similar 
increase in HK2, Ldha, Aldoc and Gapdh expression post-FcγR cross-linking, that 
was absent with LPS stimulation (SI Appendix, Fig. S1G). Together these data 
suggest that FcγR cross-linking by autoantibody-containing IgG IC initiates metabolic 
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reprogramming in tissue macrophages towards glycolysis, with the potential to 
promote pro-inflammatory activity.  
 
FcγR cross-linking in macrophages results in a switch to aerobic glycolysis 
To obtain a more detailed metabolic profile of macrophages following FcγR cross-
linking and to validate our transcriptional analyses, we measured their extracellular 
acidification rate (ECAR) and oxygen consumption rate (OCR). We found an 
increase in ECAR and a decrease in OCR following IgG IC stimulation in both 
murine BMDM (Fig. 2A, B) and human monocyte-derived macrophages (Fig. 2C). 
Overall, the ECAR/OCR ratio was significantly increased following FcγR cross-
linking (Fig. 2B, C), demonstrating a switch to glycolysis. We also observed a similar 
metabolic switch in human monocyte-derived macrophages (MDMs) using an 
alternative model of IgG IC stimulation: IgG-anti-IgG Fab immune complexes (SI 
Appendix, Fig. S2A). To determine whether these observations are representative 
of tissue macrophages, we also performed ECAR and OCR measurements in 
murine peritoneal macrophages (SI Appendix, Fig. S2B). Following Ova-IC 
stimulation, we similarly observed a switch to glycolytic metabolism, with an increase 
in ECAR, a reduction in OCR, and elevated ECAR/OCR ratio (Fig. 2D, E). 
We next performed global metabolomic profiling of IgG IC-stimulated murine 
macrophages (using Liquid chromatography–mass spectrometry) and compared 
these profiles to control or LPS-stimulated macrophages, the latter well-described to 
induce a switch to aerobic glycolysis. IgG-stimulated macrophages exhibited a 
unique metabolic profile compared with LPS-stimulated macrophages (Fig. 2F, SI 
Appendix, Fig. S2C), with specific increases in fumarate, inosine monophosphate 
(IMP), carbamoyl-aspartate (uriedosuccinic acid), and gamma-glutamylcysteine 
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relative to control or LPS-stimulated macrophages (SI Appendix, Fig. S2C, D). 
Notably, fumarate, IMP and carbamoyl-aspartate are intermediates in aspartate 
metabolism. Indeed, metabolite set enrichment analysis (MSEA) demonstrated an 
enrichment in aspartate, and phenylalanine and tyrosine metabolism pathways, as 
well as metabolites associated with the Warburg effect in IC stimulated macrophages 
(Fig. 2G), an MSEA profile that was distinct from that observed in LPS-stimulated 
macrophages (SI Appendix, Fig. S2E). In-keeping with the MSEA and seahorse 
analysis, we observed a reduction in glucose and an increase in glycolysis 
intermediates, particularly glyceraldehyde 3 phosphate, in IgG IC stimulated 
macrophages (Fig. 2H, SI Appendix, Fig. S2C). These data demonstrate that IgG 
IC induce a change in macrophage metabolism, including the induction of aerobic 
glycolysis, with a metabolic phenotype that is overlapping with, but distinct from, that 
observed with LPS stimulation. 
 
IgG immune complex-induced glycolysis is required for macrophage 
production of IL-1β, PGE2 and ROS  
FcγR crosslinking in BMDMs in vitro and tissue macrophages ex vivo induces the 
expression of several inflammatory cytokines and chemokines, including IL-1β, IL-6 
and TNFα (Fig. 3A, SI Appendix, Fig. S3A). To determine whether the observed 
glycolytic switch impacted macrophage function and their capacity to induce 
inflammation, we stimulated BMDM with IgG IC in the presence of 2-deoxy-D-
glucose (2DG), an inhibitor of glycolysis. 2DG significantly attenuated IgG IC-
induced IL-1β expression (Fig. 3B, SI Appendix, Fig. S3B) and PGE2 production 
(Fig. 3C), but had little impact on IL-6 and TNFα (Fig. 3D).  IgG IC-induced ROS 
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production was also inhibited by 2DG (Fig. 3E), while 2DG had no impact on FcγR-
mediated phagocytosis of fluorescent Ova-IC (SI Appendix, Fig. S3C). 
A single nucleotide polymorphism (SNP) in human FCGR2B (rs1050501) results in 
profound receptor dysfunction and is associated with increased susceptibility to 
lupus (7, 25). Similarly, Fcgr2b-/- mice are prone to inducible and spontaneous 
antibody-mediated autoimmune disease and have exaggerated cellular responses to 
IgG IC (1, 10). We therefore assessed whether inhibition of glycolysis with 2DG 
might negate the heightened inflammatory response associated with FcγRIIB 
deficiency. We found that IL-1β induction by Fcgr2b-/- BMDM stimulated with IgG IC 
were restored to WT levels by the addition of 2DG (Fig. 3F, SI Appendix, Fig. S3D), 
suggesting that it may potentially ameliorate macrophage-induced inflammation in 
lupus. Indeed, to confirm the relevance of these observations to SLE in humans, we 
stimulated human monocyte-derived macrophages with autoantibody-containing IC 
generated from the serum of patients with SLE (26). This caused a significant 
increase in IL1B and PTGS2 expression in macrophages that was attenuated by 
2DG (Fig. 3G).   
Given the alterations in aspartate metabolism (Fig. 2G), we also performed BMDM 
IgG IC stimulation in the presence of aminooxyacetate (AOAA), a broad-spectrum 
inhibitor of pyridoxal phosphate-dependent enzymes, including aspartate 
aminotransferase. Consistent with an important role of aspartate metabolism in 
FcγR-mediated inflammatory responses, we observed a reduction in Ova-IC-
dependent inflammatory cytokine production, including Il1b, Tnf, and Il6, in the 
presence of AOAA (Fig. 3H). 
  
FcγR-associated glycolytic switch dependent on mTOR and HIF1α  
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Next, we sought to elucidate the molecular pathways underpinning IgG IC-induced 
metabolic reprogramming in macrophages. HIF1α is a transcription factor that can 
regulate the switch to glycolysis in macrophages stimulated with LPS, and is 
essential for some aspects of the inflammatory response (27-29). We found that 
exposure of BMDM to IgG IC resulted in an increase in Hif1a transcripts, in the 
expression of several known HIF1α-target genes (Fig. 4A), as well as HIF1α protein 
(in both normoxic and hypoxic conditions) (Fig. 4B, SI Appendix, Fig. S4A) and in 
VEGFA (SI Appendix, Fig. S4B, C), a HIF1α-dependent gene that we have 
previously shown to be induced by IgG-FcγR signalling in subcapsular sinus 
macrophages in vivo (30).  Furthermore, the increase in ECAR observed following 
FcγR cross-linking was significantly attenuated in HIF1α-deficient macrophages (Fig. 
4C), demonstrating HIF1α-dependence. 
To determine the molecular pathway involved in HIF1α activation in this context, we 
targeted known kinases downstream of activating FcγRs (SI Appendix, Fig. S4D). 
Following crosslinking by immune complexes, tyrosine phosphorylation of 
intracellular ITAMs leads to the activation of SYK-family kinases and downstream 
targets, including PI3K and ERK (31-34). Small molecule inhibitors of SYK, PI3K, 
and ERK attenuated IgG IC-mediated HIF1α activation (as evidenced by VEGFA 
secretion (SI Appendix, Fig. S4E)) and the increase in ECAR in both murine (SI 
Appendix, Fig. S4F) and human macrophages (Fig. 4D), with ERK inhibition 
primarily impacting ECAR in human macrophages (Fig. 4D, SI Appendix, Fig. S4F). 
Since both PI3K and ERK can increase mammalian target of rapamycin (mTOR) 
activity by inhibiting TSC1/2 (SI Appendix, Fig. S4D), and mTOR mediates HIF1α-
induction in β-glycan treated macrophages (35), we hypothesised that FcγR-
mediated HIF1α activation might require mTOR. Consistent with this, mTOR 
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inhibitors attenuated the increase in VEGFA and ECAR observed following the 
addition of IgG IC to murine (Fig. 4E) and human macrophages (SI Appendix, Fig. 
S4G). Together these data indicate that FcγR-induced glycolysis proceeds via an 
mTOR-HIF1α-dependent pathway.  
To confirm the involvement of HIF1α in macrophage production of glycolysis-
dependent inflammatory mediators following FcγR cross-linking, we stimulated 
HIF1α-deficient macrophages with IgG IC and observed a reduction in IL-1β 
expression, PGE2, and ROS production compared with control macrophages (Fig. 
4F, G, SI Appendix, Fig. S4H). However, in contrast to 2DG treatment, there was 
also an attenuation of IL-6 and TNFα in Hif1a-/- macrophages (Fig. 4H), suggesting 
that the HIF1α-mediated increase in these cytokines is independent of its effects on 
glycolysis. 
 
Inhibiting macrophage glycolysis reduces immune complex-associated 
neutrophil recruitment in vivo. 
IL-1β is a pro-inflammatory cytokine with multiple functions in innate and adaptive 
immunity. One of its key effects is to augment inflammation by promoting neutrophil 
recruitment (36). We therefore investigated the effect of the IgG IC-mediated 
glycolytic switch in macrophages on IL-1β production and neutrophil recruitment in 
vivo. Firstly, we used, the peritoneal cavity as a model system, as described 
previously (37, 38) (SI Appendix, Fig. S5A). IgG-IC administered intraperitoneally 
were phagocytosed by peritoneal macrophages (SI Appendix, Fig. S5B). Although 
2DG administration had no effect on peritoneal macrophage phagocytosis of IgG-IC 
(SI Appendix, Fig. S5B), it significantly decreased the magnitude of IgG IC-
associated neutrophil recruitment (SI Appendix, Fig. S5C). To extend these 
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observations to a tissue context more relevant to SLE, we assessed whether a 
glycolytic switch might occur in kidney-resident macrophages in response to 
circulating IgG IC (Fig. 5A). To do this, we treated mice with 2DG prior to 
intravenous injection of Ova-IgG immune complexes or free Ova. In mice treated 
with 2DG, we observed a reduction in IgG-IC-induced expression of Il1b and Ptgs2, 
as well as Tnf and Il6 in kidney tissue (Fig. 5B), demonstrating that 2DG is effective 
in suppressing IgG-induced inflammatory gene expression within the kidney. To 
investigate immune cell responses to circulating IgG-IC, we profiled kidney 
leukocytes by flow cytometry (SI Appendix, Fig. S5D). As noted previously, kidney 
macrophages can be broadly subdivided into two major populations – F4/80hi yolk 
sac-derived macrophages (mononuclear phagocyte 1 (MNP1)) and CD11bhi F4/80int 
monocyte-derived macrophages (MNP2) (SI Appendix, Fig. S5D). Following 
intravenous administration of IgG IC, there was an increase in monocyte-derived 
MNP2 in the kidney that was independent of glycolysis (Fig. 5C).  Immune complex 
uptake was observed in both kidney macrophage populations, particularly MNP2 (SI 
Appendix, Fig. S5E) and 2DG treatment had no effect on immune complex 
phagocytosis (SI Appendix, Fig. S5E).  Despite the variation in IgG-IC phagocytosis 
between kidney MNP populations, potentially due to differences in accessibility to 
intravenous IC or subsequent processing of internalised cargo (39), analysis of 
intracellular pro-IL-1β expression in kidney macrophage subsets demonstrated an 
increase in pro-IL-1β in response to circulating IgG-IC, which was inhibited by pre-
treatment with 2DG (Fig. 5D, E).  Consistent with the decrease in macrophage IL-1β, 
2DG also attenuated IgG-IC induced neutrophil recruitment to the kidney (Fig. 5F, SI 
Appendix, Fig. S5F).  In summary, targeting glycolysis is effective in suppressing 
pro-IL-1β expression by kidney macrophages and neutrophil recruitment in vivo, 
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demonstrating the potential utility of this strategy to reduce antibody-mediated 
inflammation.  
 
Macrophage glycolytic switch as a therapeutic target in immune complex-
mediated nephritis 
Renal involvement occurs in more than half of patient with SLE and is one of the 
most serious clinical manifestations of disease (3). In murine lupus nephritis, there 
was an increase in Ighg1 expression within NZB/W kidney tissue, consistent with 
previous reports of local autoantibody production (40) (Fig. 6A), and a positive 
correlation between Ighg1 transcripts and the expression of a number of nephritis-
associated inflammatory mediators (SI Appendix, Fig. S6A, B), including IL-1β (Fig. 
6B), emphasising the potential importance of glycolysis-associated IL-1β production 
in mediating autoantibody-associated inflammation in the kidney. To explore this 
further, we administered intravenous IgG IC to MRL/MpJ control mice. This 
increased renal Hif1a and Il1b transcripts to levels observed in diseased MRL-lpr 
kidneys (Fig. 6C). There was a significant positive correlation between Hk2 and 
Hif1a and Il1b transcripts in MRL-lpr kidneys with lupus nephritis (Fig. 6D), 
implicating HIF1α-induced glycolysis in the induction of autoantibody-mediated 
inflammation in vivo. Of note, IL-1β has previously been identified in glomerular 
macrophages in diseased MRL-lpr mice (41) and our data reveal a potential 
molecular mechanism underpinning this observation.  
To test whether inhibition of the macrophage glycolytic switch might represent a 
useful strategy to reduce kidney macrophage activation in nephritis, we treated mice 
with 2DG and then challenged them with nephrotoxic serum. Inhibition of glycolysis 
reduced serum urea levels (Fig. 6E), as well as leukocyte and neutrophil recruitment 
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(Fig. 6F-G). Finally, we sought to confirm our findings in primary human kidney 
macrophages using fresh kidney samples obtained from organ donors that had 
consented for research (22).  As observed in monocyte-derived macrophages, 
treatment with 2DG decreased IL1B production following IC challenge (Fig. 6H), 
confirming the potential efficacy of this approach as a therapeutic strategy to reduce 
autoantibody-mediated inflammation in human kidneys. 
 
Discussion 
It has been recently appreciated that macrophage stimulation with pathogen-derived 
danger signals and cytokines can lead to changes in metabolism that profoundly 
impacts function (15), with LPS-stimulated M1 macrophages undergo an increase in 
glycolysis and a reduction in Krebs cycle associated OXPHOS, and IL-4-stimulated 
M2 macrophages retaining high OXPHOS (18, 19). To date, the question of whether 
and how FcγR cross-linking by IgG IC might impact macrophage metabolism has 
been explored to only a limited extent (42). Our study confirmed a previous 
description that the metabolomics changes in IgG IC-stimulated macrophages are 
distinct from those observed in LPS-treated macrophages (42).  However, we have 
gone on to show that like TLR4 stimulation, IgG immune complexes trigger a switch 
away from OXPHOS towards glycolysis, with important functional effects.  Notably, 
our transcriptomic analyses of macrophages isolated from IgG IC disease-
associated tissues consistently showed an increase in glycolysis genes, but variable 
effects on OXPHOS genes, with a reduction in synovial macrophages in RA but an 
increase in kidney macrophages in lupus nephritis.  Such differences are likely to 
reflect variability in organ-specific and disease-specific local stimuli, including 
cytokines, DAMPs, and nature of IgG (isotype, and glycosylation). By studying 
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macrophages in isolation following stimulation with only IgG IC, we confirmed the 
specific effects of FcγR cross-linking on macrophage metabolism, resulting in an 
increase in glycolysis and aspartate metabolism and a decrease in OXPHOS and 
fatty acid catabolism (Fig. 6I). 
Our experiments demonstrated that IgG IC-induced IL-1β production was HIF1α and 
glycolysis-dependent. IL-1β is a potent pro-inflammatory cytokine that has previously 
been identified in glomerular macrophages in diseased MRL-lpr mice (41) as well as 
Fcgr2b-/- mice (43), while elevated renal IL-1 family cytokine responses are common 
to several models of nephritis (Fig. S6A). Indeed, IL-1R1- or IL-1β-deficient mice are 
protected from anti-GBM IgG-mediated nephritis (44). Furthermore, it is noteworthy 
that Fcgr2b-/- mice develop fatal glomerulonephritis that is dependent on IL-17 
signalling (45), while renal Th17 cells are also observed in ANCA-associated 
glomerulonephritis in humans (46). Therefore, strategies aimed at suppressing IL-1β 
induction and downstream type 17 immune cell responses may show therapeutic 
potential in autoantibody-mediated renal inflammation. 
Our data reveal the molecular mechanisms underpinning these observations and 
identify a pathway amenable to therapeutic intervention (Fig. 6I). Tissue 
macrophages differentiate in vivo and have significant transcriptional, phenotypic 
and functional differences from monocyte- or bone marrow-derived macrophages 
and MNPs generated in vitro (47, 48). In our study, we utilised monocyte- and bone 
marrow-derived macrophages, but confirmed our findings in peritoneal macrophages 
and kidney-resident macrophages. Indeed, our use of primary human kidney 
macrophages, assayed ex vivo, provides evidence that the anti-inflammatory effects 
of inhibiting macrophage glycolytic switch will be translatable to human nephritis.  
Of note, a number of HIF1α inhibitors have been developed for clinical applications, 
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mainly for the treatment of cancers as malignant cells frequently upregulate 
HIF1α (49). These drugs target HIF1α gene expression, protein stability, protein 
degradation and DNA binding (50), and could be re-purposed for the treatment of 
autoimmune inflammation. One caveat when considering this strategy is that many 
cells express HIF1α, leading to an unfavourable side-effect profile. However, 
protocols to target HIF1α inhibitors to tissue macrophages, for example, by 
conjugating to IgG so that they are taken up by phagocytic cells expressing FcγRs or 
by placing them in nanoparticles that localise to the kidneys (51) may overcome this 
limitation. Here we focused on acute models of nephritis, but future studies will be 
required to investigate the effect of longer term HIF1α or glycolysis inhibition in 
chronic models of nephritis, such as in NZB/W mice, to determine the potential of 
these therapies for treating patients with lupus nephritis. 
 
IgG antibodies are thought to drive inflammation in a number of autoimmune 
diseases beyond SLE, including rheumatoid arthritis, small vessel vasculitis, 
Sjogrens syndrome and systemic sclerosis (52-57). Our study raises the possibility 
that tissue-resident macrophages in joints, salivary glands and skin may also be 
amenable to metabolic manipulation, as we have identified in kidney macrophages.  
In conclusion, our data reveal that IgG stimulation of macrophages can profoundly 
alter cell metabolism via HIF1α and glycolysis induction. This metabolic switch 
occurred in kidney macrophages during antibody-mediated nephritis, and glycolysis 
inhibition attenuated tissue inflammation, highlighting its potential as a therapeutic 
strategy in lupus nephritis.  
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Figure 1. FcγR cross-linking induces a glycolytic transcriptional switch in 
macrophages. (A, B) Gene set enrichment analysis (GSEA) of selected Hallmarks 
metabolic pathways in synovial macrophages from RA patients (A) and renal 
macrophages from NZB/W mice (B). Data derived from GEO: GSE10500 and 
GSE27045, respectively. (C) UMAP plot of 3353 single MNPs and associated cluster 
identities. (D) AUCell was used to test for enrichment of F4/80hi or F4/80lo gene 
signature (21), presented as a heatmap showing the row-scaled mean enrichment 
score. Increasing colour gradient indicates strength of enrichment (white to blue). (E) 
GSEA of select Hallmarks metabolic pathways in renal MNP subsets from C in 
nephritic MRL-lpr and control MRL/MpJ mice.  (F) GSEA for Hallmarks glycolysis 
pathway in BMDMs stimulated with Ova-IC for 14 h. (G) Heatmap of selected 
glycolysis genes from BMDMs shown in F.  (H) qPCR analysis of selected glycolysis 
genes in murine BMDMs stimulated with Ova or Ova-IC from 6 h.  (I) Fatty acid 
catabolism (GO: 0009062) and fatty acid biosynthesis (GO: 0006633) gene 
enrichment in BMDMs in F.  (J) Correlation analysis of single sample (ss) GSEA 
scores for Hallmarks glycolysis pathway versus top 200 IC-induced BMDM genes in 
renal macrophages from B. Mean ± s.e.m. are shown for triplicate measurements 
and are representative of three independent experiments. P values were calculated 
using the two-tailed Student’s t test (H), nonparametric Mann-Whitney U test (J), and 
Spearman’s correlation (J). * P < 0.05; ** P < 0.01, *** P < 0.001; **** P < 0.0001. 
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Figure 2. FcγR cross-linking in macrophages results in a switch to aerobic 
glycolysis. (A) ECAR and OCR in murine BMDM stimulated with Ova or Ova-IC for 
12 h were measured with a glycolysis stress test kit. (B, C) Quantification of ECAR, 
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OCR, and ECAR/OCR ratio in Ova or Ova-IC treated murine BMDM (B) and human 
MDMs (C) in the presence of glucose. Mean ± s.e.m. are shown and data are 
representative of three independent experiments. (D, E) ECAR and OCR traces (D), 
and ECAR, OCR, and ECAR/OCR measurements in the presence of glucose (E) for 
murine peritoneal macrophages stimulated as in A. Mean ± s.e.m. are shown and 
data are representative of two independent experiments. N = 6-10 per group. (F) 
Heatmap of differential metabolites in BMDMs stimulated with Ova (control), Ova-IC 
(immune complex), or LPS for 6 h. (G) Metabolite set enrichment analysis (MSEA) of 
differential metabolites in Ova-IC versus control macrophages. (H) Peak areas 
determined by mass spectrometry for glycolysis pathway metabolites altered by IgG 
IC stimulation in BMDMs stimulated as in F. P values were calculated using a two-
way ANOVA (A, D), two-tailed Student’s t test (B, C, E, H), and MSEA (G). * P < 
0.05; ** P < 0.01, *** P < 0.001; **** P < 0.0001. 
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Figure 3. IgG-induced glycolysis is required for macrophage production of 
inflammatory mediators. (A) Transcriptomic analysis of differentially expressed (P 
value < 0.05) cytokines and chemokines in BMDMs stimulated with Ova or Ova-IC 
for 4 h or 14 h. (B-D) Quantification of Il1b mRNA expression (B), PGE2 production 
(C), and IL-6 and TNFα production (D) by murine BMDMs stimulated with Ova/Ova-
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IC or unstimulated ± 2DG for 6 h. Mean ± s.e.m. are shown from triplicate 
measurements and representative of three independent experiments. (E) 
Measurement of ROS production in murine BMDM stimulated as in B-D for 2h. Total 
production of ROS in each group was quantified by calculating the Area Under the 
Curve (AUC) (right). Mean ± s.e.m. are shown from triplicate measurements and are 
representative of three independent experiments. (F) Quantification of Il1b mRNA 
production by BMDMs from WT or Fcgr2b-/- mice stimulated as in B-D. Mean ± 
s.e.m. are shown from triplicate measurements and are representative of three 
independent experiments. (G) qPCR of IL1B and PTGS2 mRNA in human MDM 
treated with IgG-IC generated by incubating serum IgG from SLE patients or healthy 
controls with RNA/Sm antigen with or without the presence of 2DG for 6 h. Data are 
normalized to unstimulated controls (Media) and HPRT1. (H) Quantification of 
cytokine expression in BMDMs stimulated with Ova/Ova-IC ± AOAA for 6 h. Mean ± 
s.e.m. are shown from 4 measurements and are representative of two independent 
experiments. P values were calculated using the two-tailed Student’s t-test. * P < 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. 
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Figure 4. HIF1α activation modulates IC-induced glycolysis switch in 
macrophages. (A) Heatmap showing transcriptomic analysis of Hif1a and HIF1α 
targets genes in murine BMDM stimulated with Ova-IC or in controls (RPMI) for 14 h. 
(B) Western blot of HIF1α protein relative to β-actin in murine BMDM ± Ova-IC 
stimulation under normoxic or hypoxic conditions. (C) HIF1α-deficient (Hif1afl/fl 
Lyz2Cre) and control (Hif1afl/fl) BMDM were stimulated with Ova or Ova-IC for 12 h. 
ECAR was measured before and after the addition of glucose. (D) ECAR was 
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measured in control (Media), IgG or IgG-Fab IC-stimulated human MDM with the 
presence of small molecule inhibitors. Macrophages were pre-treated with SYK 
inhibitor (left), ERK inhibitor (middle) or PI3K inhibitor (right) for 1 h and stimulated 
with IC (IgG-Fab) for 20 h. (E) Quantification of VEGFA in supernatants (left) and 
ECAR (right) from murine BMDM stimulated with Ova, Ova-IC or control (media) with 
or without the presence of mTOR inhibitors for 6 h. (F) Quantification of Il1b mRNA 
and PGE2 from HIF1α-deficient (Hif1afl/fl Lyz2Cre) and control (Hif1afl/fl) BMDM 
stimulated with Ova, Ova-IC or control (media) for 6 h. (G) Measurement of ROS 
production in BMDMs stimulated as in F for 2 h (left). Total production of ROS in 
each group was quantified by calculating the Area Under the Curve (AUC) (right). (H) 
Quantification of IL-6 and TNFα from HIF1α-deficient (Hif1afl/fl Lyz2Cre) and control 
(Hif1afl/fl) BMDM stimulated as in F.  All graphs show mean ± s.e.m. from triplicate 
measurements and are representative of three independent experiments. ND = not 
detected. P values were calculated using a two-way ANOVA (C) or the two-tailed 
Student’s t-test (D-H). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. 
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Figure 5. Inhibiting macrophage glycolysis reduces renal IL-1β and neutrophil 
recruitment in vivo. (A) Experiment design of the kidney-IgG IC model. (B) qPCR of 
Il1b, Tnf, Il6 and Ptgs2 mRNA in whole kidney tissue of mice treated with Ova, Ova-
IC or Ova-IC + 2DG. Data are normalized to Ova controls and Hprt. (C) MNP1 and 
MNP2 gating and quantification in kidneys from mice treated as in A. N = 6 per 
group. Means ± s.e.m. indicated. (D, E) Intracellular pro-IL-1β staining (D) and 
quantification (E) by flow cytometry for kidney MNP1 and MNP2 populations from 
mice treated as in A. N = 6 per group. Medians are indicated. (F) Quantification of 
CD11b+ Ly6C/Ghi neutrophils in mouse kidneys following Ova or Ova-IC injection 
with or without the pre-treatment of 2DG (N = 6 per group). Medians are indicated. 
Data are representative of three independent experiments. P values were calculated 
using the nonparametric Mann-Whitney U test (B, E, F). * P < 0.05, ** P < 0.01, *** P 
< 0.001, **** P < 0.0001. 
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Figure 6. Inhibition of IC-induced glycolytic switch reduces autoantibody-
mediated renal inflammation in vivo. (A) Ighg1 expression in whole kidney tissue 
from NZB/W kidneys versus controls. Means are indicated. Data derived from GEO: 
GSE27045. (B) Correlation of Il1b with Ighg1 mRNA levels in renal tissue from 
NZB/W mice shown in A. (C) qPCR of Hk2, Hif1a and Il1b mRNA in renal tissue of 
MRL/MpJ and MRL-lpr mice and MRL/MpJ mice injected with Ova-IC. Data are 
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normalized to gene expression in MRL/MpJ mice and Hprt. Means are indicated. (D) 
Correlation of glycolysis-associated genes and Il1b mRNA in renal tissue pooled 
from MRL/MpJ and MRL-lpr mice. (E) Serum urea levels in mice 24 h after i.v. 
injection of nephrotoxic serum (anti-GBM) with or without pre-treatment with 2DG. N 
= 6-7 per group. Medians indicated. (F) Representative kidney confocal images of 
mice treated as in E. (G) Quantification of neutrophils in kidneys of mice treated as in 
G. N = 4-10 per group. Medians indicated. (H) qPCR of human kidney cells 
stimulated with Ova-IC ± 2DG for 12 h. Data are normalized to Ova control and 
HPRT1. (I) Graphical summary of IgG IC-induced metabolic reprogramming in 
kidney macrophages. For in vivo experiments (C-G), medians are indicated and 
each point represents a single kidney. For human kidney stimulations, mean ± s.e.m. 
are indicated from triplicate measurements. Data are representative of two or three 
independent experiment. P values were calculated using limma with multiple 
comparisons correction using the BH procedure (A), linear regression analysis (B), 
nonparametric Mann-Whitney U test (C, E, G), or the two-tailed Student t test (H). * 









Wild-type C57BL/6 mice were obtained from the Jackson Laboratories. Hif1afl/fl and 
Lyz2Cre mice on a C57BL/6 background were obtained from the Jackson 
Laboratories and crossed to generate Hif1αfl/flLyz2Cre mice. Fcgr2b-/- mice on a 
C57BL/6 background were kindly provided by J. Ravetch (Rockefeller University) 
and S. Bolland (National Institute of Allergy and Infectious Diseases, National 
Institutes of Health). Tlr2/4-/- mice were a gift from P. Tourlomousis (University of 
Cambridge). MRL/MpJ (00486) and MRL-lpr (00485) mice were obtained from the 
Jackson Laboratories. In all experiments, both male and female mice were used. For 
all in vivo experiments, 6-12-week old mice were used. In the UK, mice were 
maintained in specific pathogen-free conditions at a Home Office-approved facility. 
All procedures were conducted in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986. In the USA, all animal study protocols were 
approved by the Animal Care and Use Committee (ACUC) of the National Institute of 
Arthritis and Musculoskeletal and Skin Diseases, were listed on animal study 
protocol AO14-01-01 and in agreement with ARAC guidelines. 3.18.1. 
Immune complexes.  
For ovalbumin immune complexes, endotoxin-free ovalbumin (321000, Hyglos 
GmbH) was opsonised with a polyclonal rabbit anti-ovalbumin antibody (C6534, 
Sigma) (1:140) (w/w) at 37 ºC for 1 h. For in vitro phagocytosis assays, Alexa Fluor 
647-conjucated ovalbumin was used (O34784, Thermo Fisher). For IgG immune 
complexes, human IgG (5172-9017, AbD Serotec) / mouse IgG (ab36355, AbCam) 
was opsonized with monoclonal human anti-human IgG antibody (HCA059, AbD 
Serotec) / goat F(ab’)2 anti-mouse IgG-(Fab’)2 antibody (ab98754, Abcam) (1:200) 
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(w/w) at 37 ºC for 1h. For in vivo experiments, 0.33 g/kg Alexa Fluor 647-conjugated 
ovalbumin (O34784, Thermo Fisher) was opsonized with 3.2 g/kg polyclonal rabbit 
anti-ovalbumin antibody (Sigma-Aldrich) at 37ºC for 1 h before injection. Details of 
systemic lupus erythematosus immune complexes are provided in the SI appendix. 
Macrophage in vitro stimulation.  
Details of the generation/isolation and culture of human MDMs, murine BMDMs, and 
murine peritoneal macrophages are provided in the SI appendix. For extracellular 
flux analysis, macrophages were pre-treated with ERK inhibitor (U0126, Sigma, 10 
μM), PI3K inhibitor (Wortmannin, 9951, Cell Signalling Technology, 1 μM), SYK 
inhibitor (Syk inhibitor IV (BAY61-3606), 1796-1,5, BioVision, 2 μM), mTOR inhibitor 
(Rapamycin, Cell Signalling Technology, 10 nM; Torin1, 14379, Cell Signalling 
Technology, 1 μM), AMPK activator (Metformin, 13118, Cayman Chemical, 3 mM) 
for 1 h before the addition of IC. Cell culture supernatants were removed and cells 
were washed using PBS before analysis. For cytokine production assay, BMDMs 
were treated with either antigens or corresponding IC (60 μg/ml) for 6 h. Cell culture 
supernatants were harvested and frozen at -20ºC until used. For glycolysis inhibition, 
macrophages were pre-treated with 2-Deoxy-D-glycose (5 mM, D8375, Sigma) for 
45 min before adding the antigens or IC for 15 min to 6 h. For aspartate 
aminotransferase inhibition, BMDMs were treated with 5 mM aminooxyacetate 
(C13408, Sigma) prior to stimulation with Ova/Ova-IC for 6h. For microarray, 2×106 
cells per well BMDMs were stimulated with either Ova (1 μg/ml) or Ova-IC (60 μg/ml) 
for 4 h or 14 h, supernatant removed and cells lysed in the plate for RNA extraction.  
Extracellular flux analysis.  
Macrophages were seeded in an XF96 microplate (Seahorse, Agilent Technology) at 
75,000 cells per well. Cells were stimulated as described above for 20 h and 
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washed/incubated with the Assay Medium (XF Base Medium (102353, Seahorse, 
Agilent Technology), sodium pyruvate (Gibco, 2mM) and L-glutamine (Gibco, 2mM)) 
in a non-CO2 incubator at 37ºC for 1 h. Oxygen consumption rate and extracellular 
acidification rate were assessed with an XF96 Extracellular Flux Analyser (Seahorse, 
Agilent Tech.). Glucose (Fisher Chemical, 10mM), oligomycin (Sigma, 1 μM) and 
2DG (Sigma, 100mM) were injected to the plate sequentially. Data was analysed 
using the XF Wave Software (Version 2.3). 
In vivo kidney macrophage stimulation.  
Wild type C57BL/6 mice were first injected with 2DG (0.25 g/kg) or PBS (control) 
intraperitoneally. After 1 h, Alexa Fluor 647-conjugated immune complexes were 
injected via tail vein at a dose of 500 ng/g. FITC conjugated anti-mouse CD45 
monoclonal antibody (clone 30-F11, eBioscience) (75 μg/kg) were injected to mice 
intravenously after 2 hours, immediately before mice were sacrificed. Kidneys were 
collected and the visceral fat and kidney capsule removed. Kidneys were finely 
minced and digested in RPMI-1640 medium containing 10 mM HEPES, 32.5 μg/ml 
Liberase TM (Roche) and 0.1 mg/ml DNase I (Roche) for 25 min at room 
temperature. Tissue pieces were mechanically dissociated through a 70 μm cell 
strainer, washed with PBS containing 2 % FBS, and red blood cell lysis performed 
using distilled H2O containing 0.83 % (w/v) NH4Cl, 0.1 % (w/v) NaHCO3, 100 mM 
EDTA. Single cell suspensions were subjected to a 44 % (v/v) Percoll (Sigma 
Aldrich) gradient and washed thoroughly in ice-cold PBS prior to downstream 
analysis. A piece of tissue from each sample was also collected and stored in 
RNAlater™ stabilization solution (AM7020, Thermo Fisher) for the qPCR. Details of 
in vivo peritoneal macrophage stimulation is provided in the SI appendix. 
Induction of lupus nephritis.  
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The anti-glomerular basement membrane (GBM) model (37, 38) was used to induce 
lupus nephritis in vivo. 50 μl of sheep anti-rat GBM serum (PTX-001S, Probetex) 
was injected intravenously to wild-type C57BL/6 mice via the tail vein. The 
proteinuria level was monitored using Multistix 10 SG Reagent Strips (Siemens, 
03536597). Mice were sacrificed after 24 h and kidneys were collected, processed 
and analysed by qPCR and flow cytometry as described above. For glycolysis 
inhibition, mice were pre-treated with 2DG (0.25 g/kg) as described above three 
times (-6 h, -3h, -1 h) before the administration of anti-GBM.  
Human kidney derived macrophages in vitro stimulation.  
Cortex samples from human kidney were sliced into approximately 30 mm3 pieces 
and digested for 30 min at 37ºC, with agitation, in a digestion solution containing 25 
μg/ml Liberase TM (Roche) and 50 μg/ml DNase (Sigma) in RPMI1640. Following 
incubation, samples were transferred to a gentle MACS C Tube (Miltenyi Biotech) 
and processed using a gentleMACS dissociator (Miltenyi Biotech) on program spleen 
4 and subsequently lung 2. The resulting suspension was passed through a 70 μm 
cell strainer (Falcon) and washed with PBS before leukocyte enrichment using a 
Percoll (Sigma) density gradient. Cells were counted using a haemocytometer with 
trypan blue. 5 x 105 cells/well were stimulated with Ova or Ova-IC with or without the 
presence of 2DG (5 mM/ml) for 12 h. Cells were then lysed and processed for RNA 
extraction and qPCR. 
Flow cytometry.  
Single cell kidney and peritoneal suspensions were blocked with 0.5 % heat-
inactivated mouse serum followed by extracellular staining for 1 h at 4 ºC with a 
combination of antibodies listed in SI appendix. Viability staining was performed with 
Zombie UV Fixable Viability Kit (Biolegend) for 20 min at room temperature. For 
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intracellular cytokine staining, cells were fixed and permeabilized using the 
Cytofix/Cytoperm kit (BD Bioscience) as per the manufacturer’s instruction. Staining 
was carried out for 1 h at room temperature using pro-IL-1β (NJTEN3, eBioscience) 
at a 1:200 dilution. Cell counting was performed using 123count eBeads 
(eBioscience). Flow cytometry data collection was performed on an LSR Fortessa 
flow cytometer (BD Biosciences) and data was analysed using FlowJo software 
(Treestar, V10.2).  
Human study approval.  
Human kidney donated for transplantation, but deemed unsuitable for implantation, 
were used for in vitro stimulation experiments. All analysis of human material was 
performed in the UK. Ethical approval was granted by the local ethics committee 
(REC12/EE/0446) and the study was also approved by NHS Blood and Transplant. 
Serum from lupus patients was collected in the US. Written informed consent was 
obtained from the healthy volunteers and from SLE patients. The enrolment of 
patients was approved by the National Institutes of Health – Institutional Review 
Board (94-AR-0066). 
Data availability. 
The microarray data reported in this paper have been deposited in the Gene 
Expression Omnibus (GEO) database, under the accession code GSE112081. 
Extended methods. 
Additional methodological details are provided in the SI appendix. 
 
 
